5 completed, 1 terminated. 3 Phase 1, 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Terminated 1 |
Follow glucokinase activator compound 50: new trials by email Literature Review of glucokinase activator compound 50 trials Research Report on glucokinase activator compound 50
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus glucokinase activator, Placebo - Type2 Diabetes Mellitus | Phase 1 | Completed | PegBio Co., Ltd. | 16 | 2019-08-27 | 2020-01-22 |
| Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects HMS5552, Placebo - Diabetes Mellitus, Type 2 | Phase 3 | Completed | Hua Medicine Limited | 767 | 2017-10-15 | 2021-08-26 |
| Long-term Efficacy and Safety of HMS5552 in T2DM Subjects HMS5552, Placebo - Diabetes Mellitus, Type 2 | Phase 3 | Completed | Hua Medicine Limited | 463 | 2017-07-18 | 2021-08-26 |
| A Study to Compare Two Forms of LY2608204 in Healthy People LY2608204 Reference, LY2608204 Test - Healthy Volunteers | Phase 1 | Completed | Eli Lilly and Company | 16 | 2011-03-01 | 2018-10-05 |
| A Study of LY2608204 in Patients With Type 2 Diabetes LY2608204 - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Eli Lilly and Company | 20 | 2010-11-01 | 2018-11-16 |
| A Study of LY2599506 in Patients With Type 2 Diabetes Placebo, LY2599506 - Diabetes Mellitus, Type 2 | Phase 2 | Terminated | Eli Lilly and Company | 78 | 2009-12-01 | 2011-12-02 |
Diabetes Mellitus, Type 2 (5) · Hypoglycemia (1)
Eli Lilly and Company (3) · Hua Medicine Limited (2) · PegBio Co., Ltd. (1)
China (3) · Singapore (2) · United States (2) · Australia (1) · Puerto Rico (1) · Russia (1) · Spain (1)
Dalong Zhu, PhD (1) · HaiYan Li (1) · Wenying Yang, MD (1)